2021/09/15 by Michael Soyka, Andreas G. Franke · 1 citation
Medicine · Pharmacology, Toxicology and Pharmaceutics · #Opioid Use Disorder Treatment #Pain Management and Opioid Use #Forensic Toxicology and Drug Analysis #Buprenorphine #Medicine #Methadone #Opioid use disorder #Opioid #Pharmacotherapy #Naltrexone #Implant #Pharmacology #Anesthesia #Internal medicine #Surgery
paper · pdf · doi:10.5498/wjp.v11.i9.543
openalex publication_date 2021/09/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade™) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine™]. The pharmacology, clinical efficacy and prospects of these medications are discussed.